Search
Tour of Scotland: St. Andrews based Pneumagen aims to prevent viral respiratory infections with an intra-nasally delivered platform that harnesses glycan targeted Carbohydrate Binding Module domains
Co-Founder & CEO Douglas Thomson describes how the company was founded, and walks us through the science. Plus, a recap of recently...
Mar 13
Tour of Scotland: Dundee based Glen Clova Scientific is using virus-like particles to lower levels of cytokines in patients experiencing chronic inflammatory conditions
CEO Steven Powell joins BiotechTV from Scotland's Life Sciences Conference and Awards in Glasgow, and explains Glen Clova's expertise in...
Mar 13
Tour of Scotland: Glasgow based Mironid is developing a small molecule to directly target aberrantly high cAMP that causes Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Co-Founder & CEO Neil Wilkie walks us through the biology of ADPKD and explains how Mironid is trying to uniquely directly target it....
Mar 13
Professor Pieter Cullis and Jay Kulkarni, co-founders of NanoVation Therapeutics, discusses the next generation of lipid nanoparticle delivery
Professor Cullis, one of the original pioneers of LNPs and co-founder of 11 biotechnology companies, describes the challenge of...
Mar 12
Tour of Scotland: Edinburgh based Trogenix is developing an AAV based gene therapy platform for cancer that is designed to deliver combination immune payloads to the tumor
CEO Ken Macnamara describes the science behind this idea and discusses recently presented preclinical data. He highlights the lead...
Mar 12
Acuitas Therapeutics is a pioneer in developing lipid nanoparticles, and already has seen two approved products: ONPATTRO and the Pfizer/BioNTech mRNA vaccine
Co-Founder & CEO Thomas Madden describes the science and history behind LNPs, and discusses what is currently in development, including...
Mar 12
Tour of Scotland: Edinburgh based Cumulus Oncology has built a hub and spoke model of creating multiple spin-out companies - it already has three disclosed assets
Founder & CEO Clare Wareing describes the company's design, with an eye towards being capital efficient and investing over and again for...
Mar 12
Tour of Scotland: Outrun Therapeutics is aiming to create a new category of therapeutics by stabilizing proteins via drugging E3 ligases
CEO Carolyn Porter describes the beginning of the company, which spun out of University of Dundee's MRC Protein Phosphorylation and...
Mar 11
Tour of Scotland: Tay Therapeutics is a product of University of Dundee's Drug Discovery Unit, and is working on small molecules - including a topical pan-BET that is in phase 2
Founder and CEO Andrew Woodland describes how they made the decision to focus on inflammation for the pan-BET, which is partnered with...
Mar 11
A study published in JMIR today showed that Limbic's GenAI-powered chatbot elevated the standard of care for mental health patients in the UK’s National Health Service (NHS)
Limbic CEO Ross Harper describes how patients who interacted with Limbic Care attended 42% more therapy sessions and achieved a 25%...
Mar 10
On Rare Disease Day, Ultragenyx's Head of Gene Therapy Research explains the company's Rare Disease Bootcamp that helps families navigate drug development, and he also talks gene therapy science
Matthew Fuller describes the course that Ultragenyx will be holding both in the Bay Area and Massachusetts. He also explains the...
Feb 28
Cambridge, UK based Amphista Therapeutics is developing a new generation of targeted protein degradation therapies that do not rely on cereblon or VHL
CEO Antony Mattessich describes the company's approach and the advantages he believes it has over other TPD. Plus, the lead program...
Feb 26
Cambridge, UK based Ignota Labs raised a $6.9M seed funding today and will use AI to understand why otherwise promising therapies have failed on tox by surprise and then to reengineer them
Co-Founder and CEO Sam Windsor describes the rationale for using AI to focus more on tox, not efficacy, and gives and example of a drug...
Feb 26
With unique license agreements in place with local universities and an additional $260M recently raised, Cambridge, UK based Apollo Therapeutics is building out a substantial pipeline
CEO Richard Mason describes the company's philosophy, and covers programs such as a FGF21/GLP-1 that was recently licensed from a Chinese...
Feb 26
Australia based Aravax, which is using a peptide based approach to food allergy treatments with the goal of avoiding inflammation, is building out late stage manufacturing capabilities in Oxford, UK
CEO Pascal Hickey introduces us to the company and describes the scale up work Aravax is doing with vendors for its lead peanut allergy...
Feb 21
Oxford based Theolytics is leveraging a library of 100M variants of adenoviruses for a bottom up approach to oncolytic virus cancer drug development
CEO David Apelian describes the importance of choosing the right strain for the right type of cancer, and discusses the company's lead...
Feb 21
With three approved products and filings for more over the near term, Axsome's CEO describes the scale and reach this company is building in the CNS space
Herriot Tabuteau updates us on the commercialization of Auvelity and Sunosi, launch plans for the recently approved Symbravo, as well as...
Feb 20
Stoke Therapeutics' CEO Ed Kaye discusses today's partnership news with Biogen on Zorevunersen for the treatment of Dravet syndrome
He describes the design of the global pivotal study, which will be initiating soon, why Stoke chose Biogen as a partner, and how today's...
Feb 18
The CEO of Solid Biosciences discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy
Bo Cumbo describes the efficacy biomarkers and safety profile they are seeing, and explains why he believes the cascade of observations...
Feb 18
John Maraganore shares his take on biotech in 2025 and discusses the science behind his recently launched RNAi company, City Therapeutics
He gives an optimistic take on the sector, describes why he thinks policy reforms can be positive but should be done strategically and...
Feb 11
.png){kind=logo}
